Prof. Emeritus Sutee Yoksan, M.D., Ph.D.
M.D., Ph.D. (Pathobiology), Mahidol University, 1989
Field of Research:Vaccine Development
Research and development on live attenuated tetravalent dengue vaccine with safety and ability to provide long lasting protective immunity has been pursued since 1980. Vaccine production was achieved by serially passages of dengue viruses in the certified cells under GLP compliance and guidance by WHO Peer Review Committee. We aim at 1-2 doses vaccine which could be able to produce a life-long protective immunity. Beside dengue vaccine, development of JE live and inactivated vaccine are also in progress with satisfactory outcome.
Facilities for laboratory testing as well as experience personnel offer CVD to serve as a WHO Reference laboratory on serology and virology for dengue and JE viruses. Samples from various countries were sent through WHO/TDR network to CVD for laboratory testing or standardizing as well as for evaluating of the vaccine products or diagnostic test kits. Training for scientists from various countries, for example, the course under PDVI programme has been successfully accomplished by the team of scientists at CVD. More than 20 years experience on dengue diagnosis has been approved not only by WHO Peer Review
Committee but also by the quality assurance teams from various private vaccine industries.
We also provide dengue and JE diagnostic on serology and virology as well as candidate vaccine evaluation for academic contribution such as; Plaque size morphology of DEN-4 parental and candidate vaccine strainsPlaque strains Preparation of certified cells for dengue vaccine Preparation vaccine. At present, networks with Thai researchers and vaccine industries from several countries have been lunched for collaboration in dengue and JE vaccine research and development. Besides, both basic and applied research leading to the development of knowledge and technologies for dengue and JE diseases are in progress and also open for collaborations.
Suputthamongkol Y., Nitatpattana N., Chayakulkeeree M., Palabodeewat S., Yoksan S., and Gonzalez JP. (2005). Hantavirus infection in Thailand: First clinical case report. . Southeast Asian J Trop Med Public Health Vol. 36 (1): 217-220.
- Nitatpattana N., Apiwathnasorn C., Barbazan P., Leemingsawat S., Yoksan S., and Gonzalez JP. (2005). First isolation of Japanese Encephalitis from Culex Quinquefasciatus in Thailand. Southeast Asian J Trop Med Public Health Vol. 36 (4): 875-878.
- Sakuntabhai A., Turbpaiboon C., Casad?mont I., Chunsumrit A., Lowhnoo T., Kajaste- Rudnitski A., Kalayanarooj S.M., Tangnararatchakit K., Tangthawornchaikul N., Vasanawathana S., Chaiyaratana W., Yenchitsomanus P., Suriyaphol P., Avirutnan, P., Chokephaibulkit K., Matsuda F., Yoksan S., Jacob Y., Lathrop M., Malasit P., Despr?s P., and Julier C. (2005). A variant in the CD209 promoter is associated with severity of dengue disease. Nature Genetics Vol. 37 (5): 507-513.
- Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., Saluzzo J.F. (2006). Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24: 1238-1241.
- Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., Yoksan S., Duan X., Ermak T.H,, Kanasan-thasan N., Bedford P., Lang J., Quentin-Millet M.J., Monath T.P. (2006). Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax?-DEN2) Vaccine: Phase I Clinical Trial For Safety and Immunogenicity, Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All 4 Dengue Serotypes. Human Vaccines 2:2, 60-67.
- Chanthavanich P., Luxemburger C., Sirivichayakul C., Lapphra K., Pengsaa K., Yoksan Y., Sabchareon A., and Lang J. (2006). Immune response and occurrence of dengue infection in Thai children 3 to 8 years after vaccination with live attenuated tetravalent dengue vaccine. Am J Trop Med Hyg. Jul;75(1):26-28.
Butthep P., Chunhakan S., Tangnararatchakit K., Yoksan S., Pattanapanyasat K., Chuansumrit A. (2006). Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. Pediatr Infect Dis J. 25: 894-897.